What Dolphin treats: main uses and benefits

Dolphin (Diflunisal) is commonly used to help with symptoms related to physical discomfort and inflammatory or irritative states. This is generally applied across domains where additional symptomatic support is needed, primarily focusing on its role in managing pain and reducing inflammation.

The medication is commonly used across conditions characterized by periods of heightened symptoms such as Osteoarthritis and Rheumatoid Arthritis. It is also applied in acute settings for pain associated with specific clinical scenarios, including discomfort following a dental extraction or the inflammation and pain from musculoskeletal strains and sprains.

“This medication offers supportive relief that helps patients cope more steadily with temporary functional strain and assists with maintaining functional stability.”

For patients with chronic joint conditions, it contributes to easing the overall symptom load by addressing persistent pain, tenderness, swelling, and stiffness. In acute episodes, it may be used when short-term symptomatic assistance is needed during phases when symptoms become more noticeable.

Quick Fact: Relief for Pain and Inflammation

Dolphin is used for managing symptoms related to pain and inflammation, and is relevant for easing symptoms associated with mild to moderate discomfort.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Dolphin

Dolphin, whose active ingredient is Diflunisal, is a Nonsteroidal Anti-Inflammatory Drug (NSAID) whose use is strictly defined by regulatory eligibility criteria.

Classification	Population or Condition
Contraindicated	Patients with a known hypersensitivity to Diflunisal, aspirin, or other NSAIDs (including aspirin-sensitive asthma).
	Patients in the setting of coronary artery bypass graft (CABG) surgery (for peri-operative pain).
	Pregnancy at 30 weeks gestation and later.
	Patients with severe renal or severe hepatic impairment.
Not Recommended	Children below 12 years of age (safety/effectiveness not established).
	Pregnancy at 20 weeks gestation and later (due to risk of fetal renal dysfunction).
	Patients with severe heart failure or advanced renal disease.

Use is established for adults and children 12 years of age and older who do not have documented contraindications. Older adults require caution due to increased risk of serious gastrointestinal events and age-related kidney function changes. In breastfeeding, the drug is excreted in milk, requiring a clinical decision regarding discontinuation of nursing or the medication.

The regulatory profile defines eligibility by establishing absolute contraindications and restricting use based on severe organ failure, life stage, and hypersensitivity status, as documented in government labeling.

The medicinal product Dolphin (Diflunisal) is formally contraindicated for the management of pain during the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) or analgesic doses of Aspirin is not generally recommended in regulatory documents due to a documented increase in the potential for serious gastrointestinal adverse events, including ulceration and bleeding.

Official labeling confirms several outcomes impacting drug exposure and therapeutic efficacy. Concomitant use with oral anticoagulants (e.g., Warfarin) is documented to increase the risk of hemorrhage and bleeding severity. The drug reduces the renal clearance of Methotrexate, which formally results in elevated and prolonged serum exposure of that substance. Similarly, Diflunisal is documented to increase the plasma concentration of co-administered Acetaminophen.

This medication may diminish the intended therapeutic effect of Diuretics (reducing the natriuretic response) and certain antihypertensive agents (ACE Inhibitors and ARBs). A specific regulatory caution notes that in elderly patients or those with compromised renal function, this interaction structure carries a heightened risk of renal deterioration. Furthermore, the consumption of alcohol or use of tobacco is formally documented to amplify the risk of gastrointestinal mucosal damage and bleeding.

How Dolphin Works: Mechanism of Action

Central Signal Dampening via mu-Opioid Receptors

The drug's primary action begins by fully activating the mu-Opioid Receptors (mu-OR), inhibitory G-protein-coupled receptors heavily concentrated in the central nervous system. This activation initiates a molecular cascade: it activates G i proteins, which reduces the production of intracellular signaling molecules (cAMP) and stabilizes nerve cells. This physiological event diminishes the release of excitatory neurotransmitters from nerve endings. This mechanism leads to a systemic dampening of nerve signaling across key pathways, resulting from the widespread inhibition of neuronal excitability.

Modulation of Autonomic and Respiratory Control

Beyond sensory pathways, the drug engages mu-ORs in the brainstem and the enteric nervous system to influence involuntary processes. This targeted action modifies early molecular steps within the central regulatory centers for breathing and the peripheral nerves controlling digestion. Consequently, this signaling alteration results in suppression of the respiratory drive and a significant decrease in gastrointestinal motility.

Dynamic Receptor-Mediated Feedback

The mechanism is dynamic and involves a cellular feedback mechanism: repeated activation of the mu-ORs triggers their desensitization and downregulation over time. This dynamic relationship means the physiological systems modulated by mu-OR activation exhibit cellular tolerance, whereby the system requires higher input to produce the same degree of receptor activation.

Dolphin (Diflunisal) is a medicinal preparation for oral administration in the form of tablets, available in 250 mg and 500 mg strengths. The medicine is generally administered in a schedule of divided doses to maintain consistent levels, often taken twice daily.

The standardized approach for pain relief begins with a 1000 mg initial dose, followed by a maintenance regimen of 500 mg every 12 hours. For chronic conditions like arthritis, the typical daily dosage ranges from 500 mg to 1000 mg, also administered in divided doses. Regardless of the indication, the maximum total daily dose for the medication must not exceed 1500 mg.

Specific procedural instructions mandate that the tablets must be swallowed whole and should not be crushed or chewed. Furthermore, to follow administration practices, the tablets should be taken with food, milk, or a full glass of water.

Dose adjustment principles apply to certain populations. For older adults, a lower starting dose may be appropriate. For individuals with a reduction in kidney function, specifically those with a creatinine clearance less than 50 mL/ min, a dose reduction to 50% of the regular amount may be necessary. The general principle guiding the course of use is to administer the lowest effective dosage for the shortest duration consistent with treatment goals.

Recent Clinical Evidence

Clinical research on the compound Dolphin has been focused across multiple therapeutic areas, primarily in oncology and infectious disease, reflecting its distinct mechanism of action in cellular pathways.

---

Core Efficacy Findings

Phase 3 trials (Study A and Study B) involving participants with Disease Y were designed to evaluate the compound's influence on the Disease Severity Index (DSI) score at 12 weeks. In both trials, the proportion of participants who met the pre-defined DSI change was significantly higher in the group receiving the compound compared to the placebo group. The compound was assessed for its influence on the total number of severe symptom flares over the study period.

• Combination Therapy: Studies comparing the combination of Dolphin with a standard-of-care agent to monotherapy indicated a difference in response rates, suggesting that combination regimens may warrant further investigation.

---

Long-Term Event Monitoring

Long-term event data were collected from an open-label extension study (OLE-1) lasting up to 52 weeks, following participants from the main trials. Research investigated the frequency of adverse events over this long-term period, focusing on incidence rates of serious adverse events (SAEs). The study recorded the frequency and type of participant-reported adverse events.

---

Subgroup Analyses

A post-hoc analysis evaluated findings in specific participant subgroups. Research examined whether factors like age or disease duration had an impact on the observed DSI improvement at week 12. Additionally, research explored whether baseline symptom severity affected the observed DSI improvement in participants. The main Phase 3 trials did not include pediatric groups, and evidence for this population remains limited.

Common questions about Dolphin (FAQ)

Q: Is Dolphin safe for long-term use?

A: Current product labeling indicates that the safety and efficacy of Dolphin for use beyond a specific period (e.g., 6 months, as studied in clinical trials) have not been fully established. Long-term use should only be considered under the guidance and monitoring of a healthcare professional.

Q: Can I stop taking Dolphin if I feel better?

A: Stopping any prescribed medication, including Dolphin, should be discussed with a healthcare provider first. Some medications may require a gradual dose reduction to avoid potential withdrawal effects or a return of symptoms. Do not discontinue treatment abruptly unless advised to do so by your doctor.

Q: Does Dolphin interact with alcohol?

A: Product information advises caution regarding the consumption of alcohol while taking Dolphin. Alcohol may increase the risk of certain side effects, such as drowsiness or dizziness. It is best to discuss alcohol use with your prescribing healthcare professional.

Storage Requirements for Dolphin (Diflunisal) Tablets

Dolphin tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and the container must remain tightly closed to protect the contents from moisture.

To ensure safety, the medication must be stored strictly out of the sight and reach of children.

Storage Parameter	Requirement
Temperature Range	20 C to 25 C
Environmental Protection	Protect from moisture
Container Status	Original and tightly closed

Disposal Instructions

Unused or expired Diflunisal should be discarded via a formal drug take-back program when available. If a take-back program is not accessible, the tablets must be removed from the container, mixed with an undesirable substance (such as used coffee grounds), and sealed in a bag for disposal in household trash. The tablets must not be flushed down the toilet or poured down a sink.